MGMT and glioblastoma: This trial prospectively confirmed the prognostic validity of MGMT promoter methylation status in GBM patients receiving current SOC treatment.2,29 Despite the survival benefit associated with MGMT promoter methylation, the OS curves remained similar for the first 12 months of follow-up, suggesting that patients with tumors bearing the methylated MGMT promoter have a better prognosis 12 months after the initial surgery.